At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
Bromocriptine 5 MG +1 moredrug
Likely dose
Bromocriptine 5 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Bromocriptine to Reduce Body Temperature in Febrile Critically-ill Adults With Acute Neurologic Disease: an Open-label, Blinded Endpoint, Randomized Controlled Trial
In Brief
A Phase 2 clinical trial evaluating Bromocriptine 5 MG and Acetaminophen 650 MG for Subarachnoid Hemorrhage and 5 related conditions. Completed, enrolled 47 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the antipyretic effect of bromocriptine in critically-ill patients with acute neurologic injury and fever from infectious and non-infectious etiologies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury, Ischemic Stroke, Fever, Intracerebral Hemorrhage
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartNov 2018
Primary CompletionNov 2019
TodayJul 2026
First PostedApr 12, 2018
Enrollment StartNov 30, 2018
Primary CompletionNov 2, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.2 years ago
Interventions
Bromocriptine 5 MGdrug
Bromocriptine 5 mg every 4 hours PO/NG/FT
Acetaminophen 650 MGdrug
Acetaminophen 650 mg every 4 hours PO/NG/FT for 48 hours